 
        
						Cecelia P. Kane 
	
					    												
Tanzania						                            
                            
						
 Research Article
												Metabolism Studies of Desvenlafaxine 						
Author(s): William DeMaio, Cecelia P. Kane, Alice I. Nichols and Ronald JordanWilliam DeMaio, Cecelia P. Kane, Alice I. Nichols and Ronald Jordan             
						
												
				 Background: This series of experiments was conducted to describe the metabolic profile of the serotonin norepinephrine reuptake inhibitor desvenlafaxine (administered as desvenlafaxine succinate) using animal and human models.   Methods: In vivo and in vitro experiments were conducted with humans and preclinical species (CD-1 mice, Sprague Dawley rats, and beagle dogs). Single oral doses of [14C]-desvenlafaxine were administered to each preclinical species for analyses of desvenlafaxine concentration in plasma, urine, and feces. Rats also were subjected to whole body autoradiography and quantitative tissue sampling. The major UDP-glucuronosyltransferase (UGT) isoforms involved in the formation of desvenlafaxine-O-glucuronide were also assessed. In vivo human experiments were conducted with healthy volunteers administered desvenlafaxine 100, 300, or 600 mg, followed by 72 hours of plas.. View More»
				  
												DOI:
												 10.4172/jbb.1000076